Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;24(7):492–499. doi: 10.1002/clc.4960240715

A critical review of clinical trials for low‐molecular‐weight heparin therapy in unstable coronary artery disease

Steen Husted 1,✉, Richard Becker 2, Andre Kher 3
PMCID: PMC6654785  PMID: 11444639

Abstract

Unstable angina and non‐ST‐segment elevation myocardial infarction (MI) are collectively referred to as unstable coronary artery disease (UCAD). They are conditions that share a common pathophysiology and represent frequently encountered, potentially life‐threatening clinical manifestations of advanced atherosclerosis. Therefore, treatment of UCAD is a major focus for practicing clinicians, and although pharmacologic agents have been developed that impact on patient outcome, recent data suggest that a further reduction in ischemic complications is possible. Acute‐phase treatment with aspirin is associated with a significant reduction in death and nonfatal MI in patients with UCAD. This benefit is enhanced by the addition of unfractionated heparin (UFH) to the treatment strategy; however, UFH requires careful monitoring and titration. in contrast, low‐molecular‐weight heparins (LMWHs), produced by chemical or enzymatic depolymerization of UFH, yield a predictable and consistent pharmacokinetic profile and anticoagulant response, making them an attractive treatment alternative to UFH in patients with UCAD. The optimal duration of treatment with LMWH is an important question influenced by the observation that reactivation of coagulation occurs following the early and abrupt discontinuation of heparin treatment. Early trials, such as FRISC and FRIC, demonstrated the benefit of acute therapy with dalteparin sodium; however, the results of extended treatment with dalteparin were inconclusive. The extended phase of these studies included relatively low‐risk patients, and a once‐daily, relatively low‐dose strategy was employed. The findings derived from the FRISC II trial, which used a twice‐daily dose of dalteparin, suggest a benefit for at least 60 days with extended treatment in high‐risk patients with UCAD. Although an early‐invasive treatment strategy is particularly beneficial, patients in whom early revascularization is not possible should be considered for extended treatment with dalteparin for up to 45 days, especially those awaiting percutaneous coronary intervention. Extended treatment with dalteparin therefore provides a protective “bridge” to enhance the outcome of patients with UCAD awaiting revascularization.

Keywords: low‐molecular‐weight heparin, unstable angina, non‐ST‐segment elevation myocardial infarction, antithrombotic therapy

Full Text

The Full Text of this article is available as a PDF (838.2 KB).

Reference

  • 1. Boden WE: Non‐Q‐acute myocardial interaction: Clinical approach to diagnosis and management In Hurst's The Update, 8th edition (Ed. O'Rourke RA.), p. 21–40. New York: McGraw‐Hill, 1996. [Google Scholar]
  • 2. Théroux P, Fuster V: Acute coronary syndromes: Unstable angina and non‐Q‐wave myocardial infarction. Circulation 1998; 97: 1195–1206. [DOI] [PubMed] [Google Scholar]
  • 3. Lewis HD, Davis JW, Archibald GD, Steinke WE, Smitherman TC, Doherty JE III, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H: Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983; 309: 396–403. [DOI] [PubMed] [Google Scholar]
  • 4. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez U, Myers MG, Sackett DL, Sealey BJ, Tanser PH: Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 1985; 313: 1369–1375. [DOI] [PubMed] [Google Scholar]
  • 5. Théroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, deGuise P, Pelletier GB, Rinzler D, Waters DD: Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105–1111. [DOI] [PubMed] [Google Scholar]
  • 6. The RISC Group : Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–830. [PubMed] [Google Scholar]
  • 7. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, Fox KA, Chesebro JH, Strain J, Keller C, Kelly A, Lancaster G, AH J, Kronmal R, Fuster V, and the Antithrombotic Therapy in Acute Coronary Syndromes Research Group : Combination antithrombotic therapy in unstable rest angina and non‐Q‐wave infarction non‐prior aspirin users: Primary end points analysis from the ATACS trial. Circulation 1994; 89: 81–88. [DOI] [PubMed] [Google Scholar]
  • 8. Holdright D, Patel D, Cunningham D, Thomas R, Hubbard W, Hendry G, Sutton G, Fox K: Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in‐hospital prognosis in patients with unstable angina. J Am Coll Cardiol 1994; 24: 39–45. [DOI] [PubMed] [Google Scholar]
  • 9. Hirsh J: Low‐molecular‐weight heparin. A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation 1998; 98 (15): 1575–1582 [DOI] [PubMed] [Google Scholar]
  • 10. Gurfinkel EP, Manos EJ, Mejail RI, Cerda MA, Duronto EA, Garcia CN, Daroca AM, Mautner B: Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am CollCardiol 1995; 26: 31–38. [DOI] [PubMed] [Google Scholar]
  • 11. FRagmin during Instability in Coronary artery disease (FRISC) study group : Low‐molecular‐weight heparin during instability in coronary artery disease, Tancef 1996; 347: 561–568. [PubMed] [Google Scholar]
  • 12. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, van der Meer J, Olaisson E, Undeland S, Ludwig K: Comparison of low‐molecular‐weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997; 96: 61–68. [DOI] [PubMed] [Google Scholar]
  • 13. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F: A comparison of low‐molecular‐weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447–452. [DOI] [PubMed] [Google Scholar]
  • 14. The FRAX.I.S. Study Group : Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6‐day treatment of unfractionated heparin in the initial management of unstable angina or non‐Q‐wave myocardial infarction: FRAX.I.S. (FRAXiparine in Ischaemic Syndrome). Eur Heart J 1999; 20: 1553–1562. [DOI] [PubMed] [Google Scholar]
  • 15. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non‐Q‐wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 1999; 100: 1593–1601. [DOI] [PubMed] [Google Scholar]
  • 16. FRagmin and Fast Revascularisation during Instability in Coronary artery disease (FRISC II) Investigators : Invasive compared with noninvasive treatment in unstable coronary artery disease. FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during Instability in Coronary artery disease Investigators. Lancet 1999; 354: 708–715. [PubMed] [Google Scholar]
  • 17. FRagmin and Fast Revascularisation during Instability in Coronary artery disease (FRISC II) Investigators : Long‐term low molecular mass heparin in unstable coronary artery disease. FRISC II prospective randomised multicentre study. Lancet 1999; 354: 701–707. [PubMed] [Google Scholar]
  • 18. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators : Dose‐ranging trial of enoxaparin for unstable angina: Results of TIMI 11A. J Am Coll Cardiol 1997; 29: 1474–1482. [PubMed] [Google Scholar]
  • 19. Eikelboom JW, Anand SS, Malmberg JI, Weitz JI, Ginsberg JS, Yusuf S: Unfractionated heparin and low‐molecular‐weight heparin in acute coronary syndrome without ST elevation: A metaanalysis. Lancet 2000; 355: 1936–1942. [DOI] [PubMed] [Google Scholar]
  • 20. Kaul S, Shah PK: Low molecular weight heparin in acute coronary syndrome: Evidence for superior or equivalent efficacy compared with unfractionated heparin? J Am Coll Cardiol 2000; 35: 1699–1712. [DOI] [PubMed] [Google Scholar]
  • 21. Théroux P, Waters D, Lam J, Juneau M, McCans J: Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327: 141–145. [DOI] [PubMed] [Google Scholar]
  • 22. Thrombin Inhibition in Myocardial Ischaemia (TRIM) Study Group : A low molecular weight, selective thrombin inhibitor, inogatran, vs. heparin, in unstable coronary artery disease in 1206 patients. Eur Heart J 1997; 18: 1416–1424. [DOI] [PubMed] [Google Scholar]
  • 23. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD: Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61–68. [DOI] [PubMed] [Google Scholar]
  • 24. Granger CB, Miller JM, Bovill EG, Gruber A, Tracy RP, Krucoff MW, Green C, Berrios E, Harrington RA, Ohman EM, Califf RM: Rebound increase in thrombin generation and activity after the cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995; 91: 1929–1935. [DOI] [PubMed] [Google Scholar]
  • 25. Lindahl B, Venge P, Wallentin L: Troponin T identifies patients with unstable coronary artery disease, who benefit from long‐term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol 1997; 29: 43–48. [DOI] [PubMed] [Google Scholar]
  • 26. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E: Outcome at 1 year after an invasive compared with a non‐invasive strategy in unstable coronary‐artery disease: The FRISC II invasive randomised trial. Lancet 2000; 356: 9–16. [DOI] [PubMed] [Google Scholar]
  • 27. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L: Markers of myocardial damage and inflammation in relation to long‐term mortality in unstable coronary artery disease. N Engl J Med 2000; 343: 1139–1147. [DOI] [PubMed] [Google Scholar]
  • 28. Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, Rutsch W, Berger J, Kootstra J, Simoons ML: Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999; 340: 1623–1629. [DOI] [PubMed] [Google Scholar]
  • 29. Bertrand ME, Simoons ML, Fox KAA, Wallentin LC, Ham CW, McFadden E, De Feyter PJ, Specchia G, Ruzyllo W: Management of acute coronary syndromes: Acute syndromes without persistent ST segment elevation. Eur Heart J 2000: 21: 1406–1432 [DOI] [PubMed] [Google Scholar]
  • 30. Kereiakes GJ, Kieiman NS, Fry E, Mwawasi G, Lengerich R, Maresh K, Burkert ML, Aquilina JW, Deloof M, Broderick TM, Shimshak TM: Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001; 141: 348–352. [DOI] [PubMed] [Google Scholar]
  • 31. Wallentin L: GUSTOIV ACS (Global Utilisation of Streptokinase and t‐PA for Occluded coronary arteries trial IV in ACS): Substudy comparing outcomes for the combination of abciximab with standard UFH or LMWH. Presented during the XXII Congress of the European Society of Cardiology, August 26–30, 2000, Amsterdam, The Netherlands; Hotline 2000. [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES